Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 2/20 | 0.52 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.32 |
| ▸ | DPYD | Q12882 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9739721 | 0.72 | MAP2K1 (0.42) | IMPDH2IMPDH1DYRK1AMCL1MAP2K1 | |
| SCHEMBL3482926 | 0.71 | ATM (0.47) | — | |
| SCHEMBL3928782 | 0.71 | GPR84 (0.36) | — | |
| SCHEMBL21380893 | 0.71 | FFAR1 (0.36) | — | |
| SCHEMBL5404703 | 0.70 | IMPDH2 (0.52) | IMPDH2IMPDH1DYRK1ALRRK2CCNT1 | |
| SCHEMBL186741 | 0.68 | IMPDH2 (1.00) | IMPDH2IMPDH1DYRK1ALRRK2APP | |
| SCHEMBL29820843 | 0.68 | IMPDH2 (1.00) | IMPDH2IMPDH1DYRK1ALRRK2APP | |
| SCHEMBL9537314 | 0.68 | IMPDH2 (0.37) | IMPDH2IMPDH1LRRK2CCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL7431978 | 0.67 | IMPDH2 (0.96) | IMPDH2IMPDH1DYRK1ALRRK2CCNT1 | |
| Hydrochloric Acid SCHEMBL7697252 | 0.67 | IMPDH2 (0.96) | IMPDH2IMPDH1DYRK1ALRRK2CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2351737-A1 | 3-Amino-1-arylpropyl indoles and aza-substituted indoles | F. Hoffmann-La Roche AG (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-7803830-B2 | 3-amino-1-arylpropyl indoles and AZA-substituted indoles and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-09-28 | — | — | US | disclosed |
| US-20090099236-A1 | 3-Amino-1-arylpropyl indoles and AZA-substituted indoles and uses thereof | ROCHE PALO ALTO LLC | 2009-04-16 | — | — | US | disclosed |
| US-7446118-B2 | 3-amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1960355-A1 | 3-AMINO-1-ARYLPROPYL INDOLES AND AZA-SUBSTITUTED INDOLES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007062996-A1 | 3-AMINO-1-ARYLPROPYL INDOLES AND AZA-SUBSTITUTED INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| US-20070123527-A1 | 3-Amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof | ROCHE PALO ALTO LLC | 2007-05-31 | — | — | US | disclosed |
| US-5254595-A | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them | ELF SANOFI (FR) | 1993-10-19 | — | — | US | disclosed |
| EP-0375560-B1 | ARYLOXYPROPANOLAMINOTETRALINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | ELF SANOFI (FR) | 1993-05-12 | — | — | EP | disclosed |
| EP-0375560-A1 | Aryloxypropanolaminotetralines, process for their preparation and pharmaceutical compositions containing same | ELF SANOFI (FR) | 1990-06-27 | — | — | EP | disclosed |
| EP-0200915-B1 | AMINOPROPANOL DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICINES CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1989-09-27 | — | — | EP | disclosed |
| US-4863949-A | CARDIOVASCULAR DISORDER TREATMENT | BOEHRINGER MANNHEIM GMBH (DE) | 1989-09-05 | — | — | US | disclosed |
| EP-0280951-A1 | Amino-propanol derivatives, process for their preparation and medicines containing these compounds, as well as intermediates | Roche Diagnostics GmbH (DE) | 1988-09-07 | — | — | EP | disclosed |
| EP-0200915-A1 | Aminopropanol derivatives, process for their preparation, their use and medicines containing them | Roche Diagnostics GmbH (DE) | 1986-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123527-A1 | 3-Amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof | IDO1, RB1, AHR | IMPDH2 720/4885IMPDH1 369/4885DYRK1A 357/4885 |
| US-20090099236-A1 | 3-Amino-1-arylpropyl indoles and AZA-substituted indoles and uses thereof | IDO1, RB1, AHR | IMPDH2 720/4885IMPDH1 369/4885DYRK1A 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.